PERIOCHIP Drug Patent Profile

When do Periochip patents expire, and when can generic versions of Periochip launch?

Periochip is a drug marketed by Dexcel Pharma and is included in one NDA.

The generic ingredient in PERIOCHIP is chlorhexidine gluconate. There are fifty-eight drug master file entries for this compound. Fifty-seven suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Periochip

A generic version of PERIOCHIP was approved as chlorhexidine gluconate by BECTON DICKINSON on October 24^th, 1989.

Summary for PERIOCHIP

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	5
Patent Applications:	7,385
What excipients (inactive ingredients) are in PERIOCHIP?	PERIOCHIP excipients list
DailyMed Link:	PERIOCHIP at DailyMed

Recent Clinical Trials for PERIOCHIP

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dexcel Pharma Technologies Ltd.	Phase 3
Dexcel Pharma Technologies Ltd.	Phase 2

See all PERIOCHIP clinical trials

US Patents and Regulatory Information for PERIOCHIP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dexcel Pharma	PERIOCHIP	chlorhexidine gluconate	TABLET;DENTAL	020774-001	May 15, 1998		DISCN	Yes	No

Expired US Patents for PERIOCHIP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Dexcel Pharma	PERIOCHIP	chlorhexidine gluconate	TABLET;DENTAL	020774-001	May 15, 1998	5,002,769
Dexcel Pharma	PERIOCHIP	chlorhexidine gluconate	TABLET;DENTAL	020774-001	May 15, 1998	5,023,082

International Patents for PERIOCHIP

See the table below for patents covering PERIOCHIP around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	80996
Japan	H03200726	SUSTAINABLY RELEASABLE CHLOROHEXYDINE COMPOSITION
Canada	2011637	COMPOSES POUR LA LIBERATION SOUTENUE DE CHLORHEXIDINE (COMPOSITIONS FOR THE SUSTAINED-RELEASE OF CHLORHEXIDINE)

PERIOCHIP Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for PerioChip

Introduction

PerioChip, a biodegradable chip containing 2.5 mg of chlorhexidine digluconate, is a significant player in the periodontal therapeutics market. It is used as a second-line treatment in the care and maintenance of periodontal disease. Here, we will delve into the market dynamics and financial trajectory of PerioChip.

Market Drivers

The periodontal therapeutics market, which includes PerioChip, is driven by several key factors:

Rise in Reported Cases of Periodontitis

The increasing prevalence of periodontitis globally is a major driver for the demand of periodontal therapeutics like PerioChip. As more people are diagnosed with periodontal diseases, the need for effective treatments rises[4].

Increase in Prevalence of Diabetes

Diabetes is a significant risk factor for periodontal diseases. The rising prevalence of diabetes worldwide contributes to the growing demand for periodontal treatments, including PerioChip[4].

Rise in Global Geriatric Population

The global geriatric population is increasing, and older adults are more prone to periodontal diseases. This demographic shift drives the demand for periodontal therapeutics[4].

Surge in Awareness About Oral Health

Increased awareness about oral health and the importance of maintaining good periodontal health also drives the market for products like PerioChip[4].

Clinical Efficacy

PerioChip has been clinically proven to be effective in reducing pocket depth in patients with periodontitis.

Clinical Studies

Studies have shown that patients treated with PerioChip in addition to scaling and root planing (SRP) experienced a statistically significant reduction in periodontal pocket depth compared to those treated with SRP alone. For example, in two U.S. multicenter studies, approximately twice as many subjects treated with PerioChip + SRP showed an improvement in pocket depth of 2 mm or more at nine months compared to those treated with SRP alone[3].

Targeted Delivery

PerioChip provides targeted delivery of chlorhexidine digluconate, reaching the base of periodontal pockets and killing 99% of periopathogenic bacteria. This localized action enhances its efficacy in reducing pocket depth and improving attachment levels[5].

Market Segmentation

The periodontal therapeutics market, including PerioChip, is segmented by product type and distribution channels.

Product Type

• Local Antibiotics: PerioChip falls under this category, which is expected to account for a significant share of the periodontal therapeutics market. Other local antibiotics include Arestin and Atridox[4].

Distribution Channels

• Hospitals Pharmacies: These are major distribution channels for PerioChip.
• Retail Pharmacies: PerioChip is also available through retail pharmacies.
• Drug Stores: Another distribution channel for PerioChip.
• E-commerce: The rise of e-commerce has also made PerioChip more accessible to patients[4].

Regional Market Analysis

The market for PerioChip is analyzed across various regions:

North America

North America is a significant market for periodontal therapeutics, driven by high awareness of oral health and advanced healthcare infrastructure. The U.S. and Canada are key countries in this region[4].

Europe

Europe also represents a substantial market, with countries like Germany, the U.K., France, and Italy contributing to the demand for PerioChip[4].

Asia Pacific

The Asia Pacific region is growing rapidly due to increasing healthcare expenditure and a rising geriatric population. Countries like Japan, China, and India are key markets[4].

Latin America and Middle East & Africa

These regions are also experiencing growth, driven by increasing awareness of oral health and improving healthcare infrastructure[4].

Financial Trajectory

The periodontal therapeutics market, which includes PerioChip, is expected to grow significantly.

Market Size and Growth Rate

The global periodontal therapeutics market is anticipated to reach US$ 1.1 billion by 2027, expanding at a CAGR of 8.8% from 2019 to 2027[4].

Revenue Forecast

The local antibiotics segment, which includes PerioChip, is expected to account for a significant share of the market revenue. The market value forecast by product and distribution channel indicates a steady increase in revenue for PerioChip and similar products[4].

Competition Landscape

PerioChip competes with other local antibiotics such as Arestin and Atridox. Key players in the periodontal therapeutics market include Den-Mat Holdings, LLC, Valeant Pharmaceuticals International, Inc., Dexcel Pharma, 3M Company, Oral Science, and Kaken Pharmaceutical Co., Ltd[4].

Key Takeaways

• Clinical Efficacy: PerioChip is clinically proven to reduce pocket depth and improve attachment levels in patients with periodontitis.
• Market Drivers: The market is driven by the rise in reported cases of periodontitis, increase in prevalence of diabetes, rise in global geriatric population, and surge in awareness about oral health.
• Market Segmentation: The market is segmented by product type and distribution channels, with local antibiotics being a significant segment.
• Regional Market: The market is analyzed across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
• Financial Trajectory: The market is expected to grow at a CAGR of 8.8% to reach US$ 1.1 billion by 2027.

FAQs

What is PerioChip used for?

PerioChip is used as a second-line treatment in the care and maintenance of periodontal disease. It is an innovative, easy-to-insert biodegradable chip containing 2.5 mg of chlorhexidine digluconate.

How effective is PerioChip in treating periodontitis?

PerioChip has been shown to be significantly more effective in reducing pocket depth than scaling and root planing (SRP) alone. It provides targeted delivery of chlorhexidine digluconate, killing 99% of periopathogenic bacteria[3].

What are the key distribution channels for PerioChip?

PerioChip is distributed through hospitals pharmacies, retail pharmacies, drug stores, and e-commerce platforms[4].

Who are the key players in the periodontal therapeutics market?

Key players include Den-Mat Holdings, LLC, Valeant Pharmaceuticals International, Inc., Dexcel Pharma, 3M Company, Oral Science, and Kaken Pharmaceutical Co., Ltd[4].

What is the expected market size of the periodontal therapeutics market by 2027?

The global periodontal therapeutics market is anticipated to reach US$ 1.1 billion by 2027, expanding at a CAGR of 8.8% from 2019 to 2027[4].

Sources

1. Biospace: Periodontal Therapeutics Market Share, Industry Growth, Trend, Drivers, Challenges, Key Companies by 2028.
2. University of Michigan: Research expenditures and awards.
3. PerioChip: Research - PerioChip.
4. Transparency Market Research: Periodontal Therapeutics Market Analysis Report 2027.
5. PerioChip: Home - PerioChip.